Author:
Zhou Changsheng,Li Ming,Ren Yantao,Miao Fenglin,Wang Yue,Wu Ting,Gou Xin,Li Wengang
Abstract
Abstract
Background
Tumor immunotherapy is a new treatment breakthrough for retroperitoneal liposarcoma (RPLS), which is highly invasive and has few effective treatment options other than tumor resection. However, the heterogeneity of the tumor immune microenvironment (TIME) leads to missed clinical diagnosis and inappropriate treatment. Therefore, it is crucial to evaluate whether the TIME of a certain part of the tumor reliably represents the whole tumor, particularly for very large tumors, such as RPLS.
Methods
We conducted a prospective study to evaluate the TIME in different regions of dedifferentiated RPLS (DDRPLS) by detecting the expressions of markers such as CD4+, CD8+, Foxp3+, CD20+, CD68+, LAMP3+, PD-1+ tumor-infiltrating lymphocytes (TILs), and PD-L1 in tumors and corresponding paratumor tissues via immunohistochemistry and RNA sequencing.
Results
In DDRPLS, very few TILs were observed. Differentially expressed genes were significantly enriched in cell part and cell functions, as well as the metabolic pathway and PI3K-Akt signaling pathway. In addition, for most tumors (70–80%), the TIME was similar in different tumor regions.
Conclusions
For most tumors (70–80%), the TIME in any region of the tumor reliably represents the whole tumor. DDRPLS may regulate cell functions by modulating the metabolic and PI3K-Akt signaling pathways to promote its malignant behavior.
Funder
Natural Science Foundation of Guizhou Province
Beijing Medical and health public welfare foundation
Young and Middle-Aged Backbone Talent Training Program of Fujian Health Commission
Key Project of the Science and Technology Ministry of China
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Xue G, Wang Z, Li C, Lv A, Tian X, Wu J, Qiu H, Hao C. A novel nomogram for predicting local recurrence-free survival after surgical resection for retroperitoneal liposarcoma from a Chinese tertiary cancer center. Int J Clin Oncol. 2021;26:145–53.
2. Yan L, Wang Z, Cui C, Guan X, Dong B, Zhao M, Wu J, Tian X, Hao C. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma. Cancer Sci. 2019;110:3038–48.
3. Yan Y, Xia S, Teng D, Hu S, Li S, Wang Y, Du X, Li R. Resection outcomes for primary and local recurrent retroperitoneal liposarcoma patients. Ann Transl Med. 2020;8:1450.
4. Paloyo SR, Ramirez AD, David-Paloyo FP, Dofitas RB. Wide excision of a retroperitoneal liposarcoma with en bloc ureterectomy and renal salvage by autotransplantation. Case Rep Transplant. 2019;2019:9725169.
5. Matsunaga T, Yamaguchi T, Kaida S, Takebayashi K, Murata S, Shimizu T, Sonoda H, Miyake T, Ueki T, Iida H, et al. Study of eight cases of retroperitoneal liposarcoma. Gan To Kagaku Ryoho. 2019;46:2104–6.